Vijay Padul, PhD
Sr. Scientist – Omics
Vijay Padul is a Senior Scientist at Rhenix, where he leads bioinformatics, genomics, and Next Generation Sequencing research-related activities, in the organization. He is currently working on the neoantigen cancer vaccine pipeline projects.
Vijay holds a Ph.D. in Life Sciences from TMC-ACTREC, Homi Bhabha National Institute, Navi Mumbai. His Ph.D. study focused on Cancer Genomics. Previously, Vijay has worked as an Assistant Professor at graduate and post-graduate degree colleges as well.
At Rhenix, he has gained experience in scientific, operational, and administrative matters.
Stories
Summary "A phase Ib-IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma- CUSP9v3-2021"
Glioblastoma is the most common and aggressive primary malignant brain tumor in adults. Despite therapeutic interventions, glioblastoma prognosis remains very poor as most patients die…
Summary "An effective integrated grading system for meningioma tumor grading that incorporates molecular features."
Meningioma is the most common primary intracranial tumor in the United States. There are approximately 35,000 new cases diagnosed every year. meningioma has an estimated population prevalence of approximately...
Videos
A phase Ib-IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma- CUSP9v3-2021 | Cell talk
Glioblastoma is the most common and aggressive primary malignant brain tumor in adults. Despite therapeutic interventions, glioblastoma prognosis remains very poor as most patients die…
An effective integrated grading system for meningioma tumor grading that incorporates molecular features.
Meningioma is the most common primary intracranial tumor in the United States. There are approximately 35,000 new cases diagnosed every year. meningioma has an estimated population prevalence of approximately...